Fenwick Guides Cancer Biotech Loxo's $120M Follow-On
Loxo Oncology Inc., a biopharmaceutical company focused on developing treatments for select cancers, said Thursday that it has priced a $120 million follow-on offering to help fund commercialization, research and development...To view the full article, register now.
Already a subscriber? Click here to view full article